A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

INTRODUCTION: Lurbinectedin is a selective inhibitor of oncogenic transcription U.S. Food and Drug Administration (FDA)-approved for patients with relapsed small cell lung cancer (SCLC) as monotherapy at 3.2 mg/m(2) every 3 weeks (q3wk). ATLANTIS was a phase 3 study in SCLC with lurbinectedin 2.0 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Fudio, Salvador, Pérez-Ramos, Laura, Asín-Prieto, Eduardo, Zeaiter, Ali, Lubomirov, Rubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311440/
https://www.ncbi.nlm.nih.gov/pubmed/37397388
http://dx.doi.org/10.3389/fonc.2023.1152371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311440/
https://www.ncbi.nlm.nih.gov/pubmed/37397388
http://dx.doi.org/10.3389/fonc.2023.1152371

Ejemplares similares